Protons against cancer: New research beamline for innovative radiotherapies

Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB.

Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB

Magnetic quadrupoles focus the proton beam in front of the experiment platform.

Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB

Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.

 

The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.

Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.

‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.

arö

  • Copy link

You might also be interested in

  • Theory meets practice – We’re heading back to HTW Berlin!
    News
    07.04.2026
    Theory meets practice – We’re heading back to HTW Berlin!
    The HZB’s BIPV consultancy office (BAIP) is once again coordinating and delivering the lecture series “Building-Integrated Photovoltaics”.
  • AI-driven Catalyst Discovery: €30 million funding for German consortium
    News
    30.03.2026
    AI-driven Catalyst Discovery: €30 million funding for German consortium
    Six partners from research and industry, including Helmholtz-Zentrum Berlin (HZB), the Fritz-Haber-Institute of the Max Planck Society (FHI), BASF, Dunia Innovations, Siemens Energy, and the Technical University Berlin are launching a joint project to accelerate the catalyst discovery. The German Federal Ministry for Science, Technology and Space (BMFTR) is providing €30 million in funding for ASCEND (Accelerated Solutions for Catalysis using Emerging Nanotechnology and Digital Innovation). The research initiative targets the defossilisation of energy-intensive industries while safeguarding industrial competitiveness, with a focus on the chemical sector. The five-year project will start on 1st April 2026.
  • Kick-off for a new data and AI centre in Berlin
    News
    27.03.2026
    Kick-off for a new data and AI centre in Berlin
    By establishing a new data and AI centre in Berlin, the Zuse Institute Berlin (ZIB) and the Helmholtz-Zentrum Berlin (HZB) are laying the foundations for a scalable and sovereign data infrastructure in the capital. The project strengthens the scientific capabilities of Berlin’s research community whilst making an important contribution to research security, resilience and technological independence.